These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 28017405)
1. Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. Grobusch MP; Goorhuis A Lancet; 2017 Feb; 389(10069):578-580. PubMed ID: 28017405 [No Abstract] [Full Text] [Related]
2. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399 [TBL] [Abstract][Full Text] [Related]
4. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765 [TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831 [TBL] [Abstract][Full Text] [Related]
6. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. Choi JH; Schafer SC; Freiberg AN; Croyle MA Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Bergren NA; Miller MR; Monath TP; Kading RC Hum Vaccin Immunother; 2018 Apr; 14(4):994-1002. PubMed ID: 29206076 [TBL] [Abstract][Full Text] [Related]
11. Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Mennechet FJ; Tran TT; Eichholz K; van de Perre P; Kremer EJ Expert Rev Vaccines; 2015; 14(11):1471-8. PubMed ID: 26325242 [TBL] [Abstract][Full Text] [Related]
12. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS; Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824 [TBL] [Abstract][Full Text] [Related]
13. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]
14. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907 [No Abstract] [Full Text] [Related]
15. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S J Virol; 2017 May; 91(10):. PubMed ID: 28250127 [TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
18. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525 [TBL] [Abstract][Full Text] [Related]
19. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166 [TBL] [Abstract][Full Text] [Related]